Template:Percutaneous Coronary Intervention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(19 intermediate revisions by 4 users not shown) | |||
Line 3: | Line 3: | ||
| colspan="1" style="text-align:center; background:DarkGray" | | | colspan="1" style="text-align:center; background:DarkGray" | | ||
'''Percutaneous Coronary Intervention Microchapters | '''Percutaneous Coronary Intervention Guidelines Microchapters | ||
''' | ''' | ||
|- bgcolor="LightGrey" | |- bgcolor="LightGrey" | ||
Line 10: | Line 10: | ||
|- bgcolor="LightCoral" | |- bgcolor="LightCoral" | ||
! | ! | ||
[[Percutaneous | [[Percutaneous coronary intervention: basic principles and guidelines|Home]] | ||
|- | |- | ||
! | ! | ||
Line 20: | Line 20: | ||
! | ! | ||
|- bgcolor="Pink" | |||
! | |||
[[Percutaneous coronary intervention overview|Overview]] | |||
|- | |||
! | |||
|- bgcolor="CadetBlue" | |- bgcolor="CadetBlue" | ||
! | ! | ||
PCI Approaches: | |||
|- | |- | ||
! | ! | ||
|- bgcolor="CadetBlue" | |||
|- bgcolor=" | |||
! | ! | ||
CAD Revascularization: | CAD Revascularization: | ||
Line 34: | Line 38: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention heart team approach to revascularization decisions|Heart Team Approach to Revascularization Decisions]] | ||
|- | |- | ||
! | ! | ||
Line 40: | Line 44: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention left main coronary artery disease|Left Main Coronary Artery Disease]] | ||
|- | |- | ||
! | ! | ||
Line 46: | Line 50: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[ | :::[[Intervention in left main coronary artery disease]] | ||
|- | |- | ||
! | ! | ||
Line 52: | Line 56: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous Coronary | ::[[Percutaneous coronary intervention non-left main coronary artery disease|Non-Left Main Coronary Artery Disease]] | ||
|- | |- | ||
! | ! | ||
Line 58: | Line 62: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention revascularization to improve symptoms|Revascularization to Improve Symptoms]] | ||
|- | |- | ||
! | ! | ||
Line 64: | Line 68: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention dual antiplatelet therapy compliance and stent thrombosis|Dual Antiplatelet Therapy Compliance and Stent Thrombosis]] | ||
|- | |- | ||
! | ! | ||
Line 70: | Line 74: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous coronary intervention hybrid coronary revascularization|Hybrid Coronary Revascularization]] | |||
|- | |- | ||
! | ! | ||
|- bgcolor=" | |- bgcolor="CadetBlue" | ||
! | ! | ||
: | Pre-procedural Considerations: | ||
|- | |- | ||
! | ! | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention contrast-induced acute kidney injury|Contrast-Induced Acute Kidney Injury]] | ||
|- | |- | ||
! | ! | ||
Line 88: | Line 92: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention anaphylactoid reactions|Anaphylactoid Reactions]] | ||
|- | |- | ||
! | ! | ||
Line 94: | Line 98: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention statin treatment|Statin Treatment]] | ||
|- | |- | ||
! | ! | ||
Line 100: | Line 104: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention bleeding risk|Bleeding Risk]] | ||
|- | |- | ||
! | ! | ||
Line 106: | Line 110: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention role of onsite surgical backup|Role of Onsite Surgical Backup]] | ||
|- | |- | ||
! | ! | ||
|- bgcolor=" | |- bgcolor="CadetBlue" | ||
! | ! | ||
Procedural Considerations: | Procedural Considerations: | ||
Line 118: | Line 122: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous coronary intervention vascular access|Vascular Access]] | |||
|- | |- | ||
! | ! | ||
Line 130: | Line 134: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention asymptomatic ischemia or CCS class I or II angina|Asymptomatic Ischemia or CCS Class I or II Angina]] | ||
|- | |- | ||
! | ! | ||
Line 136: | Line 140: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention CCS class III angina|CCS Class III Angina]] | ||
|- | |- | ||
! | ! | ||
Line 142: | Line 146: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention unstable Angina/non-ST-elevation myocardial infarction|Unstable Angina/Non–ST-Elevation Myocardial Infarction]] | ||
|- | |- | ||
! | ! | ||
Line 148: | Line 152: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:: | ::ST-Elevation Myocardial Infarction: | ||
|- | |- | ||
! | ! | ||
Line 154: | Line 158: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:::[[Percutaneous | :::[[Percutaneous coronary intervention general and specific considerations|General and Specific Considerations]] | ||
|- | |- | ||
! | ! | ||
Line 160: | Line 164: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:::[[Percutaneous Coronary | :::[[Percutaneous coronary intervention coronary angiography strategies in STEMI|Coronary Angiography Strategies in STEMI]] | ||
|- | |- | ||
! | ! | ||
Line 166: | Line 170: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:::[[Percutaneous | :::[[Percutaneous coronary intervention primary PCI of the infarct artery|Primary PCI of the Infarct Artery]] | ||
|- | |- | ||
! | ! | ||
Line 172: | Line 176: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:::[[Percutaneous | :::[[Percutaneous coronary intervention delayed or elective PCI in patients with STEMI|Delayed or Elective PCI in patients with STEMI]] | ||
|- | |- | ||
! | ! | ||
Line 178: | Line 182: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:::[[Percutaneous | :::[[Percutaneous coronary intervention fibrinolytic-ineligible patients|Fibrinolytic-Ineligible Patients]] | ||
|- | |- | ||
! | ! | ||
Line 184: | Line 188: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:::[[Percutaneous | :::[[Percutaneous coronary intervention facilitated PCI|Facilitated PCI]] | ||
|- | |- | ||
! | ! | ||
Line 190: | Line 194: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:::[[Percutaneous | :::[[Percutaneous coronary intervention rescue PCI (PCI after failed fibrinolysis)|Rescue PCI]] | ||
|- | |- | ||
! | ! | ||
Line 196: | Line 200: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:::[[Percutaneous | :::[[Percutaneous coronary intervention after successful fibrinolysis or for patients not undergoing primary reperfusion|After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion]] | ||
|- | |- | ||
! | ! | ||
Line 202: | Line 206: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention Cardiogenic shock|Cardiogenic Shock]] | ||
|- | |- | ||
! | ! | ||
Line 208: | Line 212: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention prior coronary bypass surgery|Prior Coronary Bypass Surgery]] | ||
|- | |- | ||
! | ! | ||
Line 214: | Line 218: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention revascularization before non-cardiac surgery|Revascularization Before Non-cardiac Surgery]] | ||
|- | |- | ||
! | ! | ||
Line 220: | Line 224: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
: | :Adjunctive Diagnostic Devices: | ||
|- | |- | ||
! | ! | ||
Line 226: | Line 230: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
: | ::[[Percutaneous coronary intervention fractional flow reserve|Fractional Flow Reserve]] | ||
|- | |- | ||
! | ! | ||
Line 232: | Line 236: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention intravascular ultrasound|Intravascular Ultrasound]] | ||
|- | |- | ||
! | ! | ||
Line 238: | Line 242: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:: | :Adjunctive Therapeutic Devices: | ||
|- | |- | ||
! | ! | ||
Line 244: | Line 248: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
: | ::[[Percutaneous coronary intervention coronary atherectomy|Coronary Atherectomy]] | ||
|- | |- | ||
! | ! | ||
Line 250: | Line 254: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention thrombectomy|Thrombectomy]] | ||
|- | |- | ||
! | ! | ||
Line 256: | Line 260: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention laser angioplasty|Laser Angioplasty]] | ||
|- | |- | ||
! | ! | ||
Line 262: | Line 266: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention cutting balloon angioplasty|Cutting Balloon Angioplasty]] | ||
|- | |- | ||
! | ! | ||
Line 268: | Line 272: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention embolic protection devices|Embolic Protection Devices]] | ||
|- | |- | ||
! | ! | ||
Line 274: | Line 278: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous coronary intervention percutaneous hemodynamic support devices|Percutaneous Hemodynamic Support Devices]] | |||
|- | |- | ||
! | ! | ||
Line 280: | Line 284: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
: | :Antiplatelet therapy: | ||
|- | |- | ||
! | ! | ||
Line 286: | Line 290: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:Antiplatelet | ::[[Percutaneous coronary intervention oral antiplatelet therapy|Oral Antiplatelet Therapy]] | ||
|- | |- | ||
! | ! | ||
Line 292: | Line 296: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention Glycoprotein IIb/IIIa Receptor Antagonists|Glycoprotein IIb/IIIa Receptor Antagonists]] | ||
|- | |- | ||
! | ! | ||
Line 304: | Line 308: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::::[[Percutaneous | ::::[[Percutaneous coronary intervention ST-elevation myocardial infarction (STEMI)|STEMI]] | ||
|- | |- | ||
! | ! | ||
Line 310: | Line 314: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::::[[Percutaneous | ::::[[Percutaneous coronary intervention unstable angina / non-ST elevation myocardial infarction (UA/NSTEMI)|UA/NSTEMI]] | ||
|- | |- | ||
! | ! | ||
Line 316: | Line 320: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::::[[Percutaneous | ::::[[Percutaneous coronary intervention sudden ischemia heart disease (SIHD)|SIHD]] | ||
|- | |- | ||
! | ! | ||
Line 322: | Line 326: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:Anticoagulant Therapy: | |||
|- | |- | ||
! | ! | ||
Line 328: | Line 332: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention use of parenteral anticoagulants during PCI|Parenteral Anticoagulants During PCI]] | ||
|- | |- | ||
! | ! | ||
Line 334: | Line 338: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention unfractionated heparin|Unfractionated Heparin]] | ||
|- | |- | ||
! | ! | ||
Line 340: | Line 344: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention enoxaparin|Enoxaparin]] | ||
|- | |- | ||
! | ! | ||
Line 346: | Line 350: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention bivalirudin and argatoban|Bivalirudin and Argatroban]] | ||
|- | |- | ||
! | ! | ||
Line 352: | Line 356: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention fondaparinux|Fondaparinux]] | ||
|- | |- | ||
! | ! | ||
Line 358: | Line 362: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention no-reflow pharmacological therapies|No-Reflow Pharmacological Therapies]] | ||
|- | |- | ||
! | ! | ||
Line 364: | Line 368: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:PCI in Specific Anatomic Situations: | |||
|- | |- | ||
! | ! | ||
Line 370: | Line 374: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention chronic total occlusions|Chronic Total Occlusions]] | ||
|- | |- | ||
! | ! | ||
Line 376: | Line 380: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention saphenous vein grafts|Saphenous Vein Grafts]] | ||
|- | |- | ||
! | ! | ||
Line 382: | Line 386: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention bifurcation lesions|Bifurcation Lesions]] | ||
|- | |- | ||
! | ! | ||
Line 388: | Line 392: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention aorto-ostial stenoses|Aorto-Ostial Stenoses]] | ||
|- | |- | ||
! | ! | ||
Line 394: | Line 398: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention calcified lesions|Calcified Lesions]] | ||
|- | |- | ||
! | ! | ||
Line 400: | Line 404: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:PCI in Specific Patient Populations: | |||
|- | |- | ||
! | ! | ||
Line 406: | Line 410: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
::[[Percutaneous | ::[[Percutaneous coronary intervention chronic kidney disease|Chronic Kidney Disease]] | ||
|- | |- | ||
! | ! | ||
Line 412: | Line 416: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention peri-procedural myocardial infarction assessment|Peri-procedural Myocardial Infarction Assessment]] | ||
|- | |- | ||
! | ! | ||
Line 418: | Line 422: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention vascular closure devices|Vascular Closure Devices]] | ||
|- | |- | ||
! | ! | ||
|- bgcolor=" | |- bgcolor="CadetBlue" | ||
! | ! | ||
Post-Procedural Considerations: | Post-Procedural Considerations: | ||
Line 430: | Line 434: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention post-procedural antiplatelet therapy|Post-procedural Antiplatelet Therapy]] | ||
|- | |- | ||
! | ! | ||
Line 436: | Line 440: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy|Proton Pump Inhibitors and Antiplatelet Therapy]] | |||
|- | |- | ||
! | ! | ||
Line 442: | Line 446: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous coronary intervention clopidogrel genetic testing|Clopidogrel Genetic Testing]] | |||
|- | |- | ||
! | ! | ||
Line 448: | Line 452: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous coronary intervention platelet function testing|Platelet Function Testing]] | |||
|- | |- | ||
! | ! | ||
Line 454: | Line 458: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention restenosis|Restenosis]] | ||
|- | |- | ||
! | ! | ||
Line 460: | Line 464: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous coronary intervention exercise testing|Exercise Testing]] | |||
|- | |- | ||
! | ! | ||
Line 466: | Line 470: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous coronary intervention cardiac rehabilitation|Cardiac Rehabilitation]] | |||
|- | |- | ||
! | ! | ||
|- bgcolor=" | |- bgcolor="CadetBlue" | ||
! | ! | ||
Quality and Performance Considerations: | |||
|- | |- | ||
! | ! | ||
Line 478: | Line 482: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention quality and performance|Quality and Performance]] | ||
|- | |- | ||
! | ! | ||
Line 484: | Line 488: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention certification and maintenance of certification|Certification and Maintenance of Certification]] | ||
|- | |- | ||
! | ! | ||
Line 490: | Line 494: | ||
|- bgcolor="PaleTurquoise" | |- bgcolor="PaleTurquoise" | ||
! | ! | ||
:[[Percutaneous | :[[Percutaneous coronary intervention operator and institutional competency and volume|Operator and Institutional Competency and Volume]] | ||
|- | |- | ||
! | ! |
Latest revision as of 13:16, 21 June 2022
Percutaneous Coronary Intervention Guidelines Microchapters |
PCI Approaches: |
---|
CAD Revascularization: |
Pre-procedural Considerations: |
Procedural Considerations: |
|
|
|
|
|
|
|
|
|
Post-Procedural Considerations: |
Quality and Performance Considerations: |
Percutaneous Coronary Intervention On the Web |
American Roentgen Ray Society Images of Percutaneous Coronary Intervention |
Directions to Hospitals Treating Percutaneous Coronary Intervention |
Risk calculators and risk factors for Percutaneous Coronary Intervention |